Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorAMMASSARI, A.
dc.contributor.authorSTOHR, W.
dc.contributor.authorANTINORI, A.
dc.contributor.authorMOLINA, J. M.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSCHWIMMER, Christine
dc.contributor.authorDOMINGO, P.
dc.contributor.authorTHALME, A.
dc.contributor.authorDI PIETRO, M.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorWALLET, Cedrick
dc.contributor.authorPOZNIAK, A.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorRICHERT, Laura
dc.contributor.authorRAFFI, F.
dc.date.accessioned2020-10-19T08:10:07Z
dc.date.available2020-10-19T08:10:07Z
dc.date.issued2018-08-27
dc.identifier.issn1944-7884 (Electronic) 1525-4135 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/11405
dc.description.abstractEnBACKGROUND: The NEAT 001/ANRS 143 trial demonstrated non-inferiority of darunavir-ritonavir combined with either raltegravir (RAL+DRV/r) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC+DRV/r) in HIV-positive, antiretroviral-naive adults. In post-hoc analyses however, RAL+DRV/r showed inferiority in patients with baseline CD4+ <200/mm and HIV-1 RNA >/=100,000 copies/mL. This pre-planned ancillary study was conducted to assess whether differences in adherence might explain efficacy results SETTING
dc.language.isoENen_US
dc.subject.enSISTM
dc.title.enPatient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined with Either Raltegravir or Tenofovir Disoproxil Fumarate /Emtricitabine in the Neat 001/Anrs 143 Trial
dc.title.alternativeJ Acquir Immune Defic Syndren_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1097/qai.0000000000001834en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed30153121en_US
bordeaux.journalJournal of acquired immune deficiency syndromes (1999)en_US
bordeaux.page481-490en_US
bordeaux.volume79en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue4en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamSISTM_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Journal%20of%20acquired%20immune%20deficiency%20syndromes%20(1999)&amp;rft.date=2018-08-27&amp;rft.volume=79&amp;rft.issue=4&amp;rft.spage=481-490&amp;rft.epage=481-490&amp;rft.eissn=1944-7884%20(Electronic)%201525-4135%20(Linking)&amp;rft.issn=1944-7884%20(Electronic)%201525-4135%20(Linking)&amp;rft.au=AMMASSARI,%20A.&amp;STOHR,%20W.&amp;ANTINORI,%20A.&amp;MOLINA,%20J.%20M.&amp;SCHWIMMER,%20Christine&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée